Sanofi unveils mixed news for Zaltrap cancer drug

PARIS Thu Apr 5, 2012 11:23am IST

Related Topics

Stocks

   

PARIS (Reuters) - Sanofi and Regeneron Pharmaceuticals said their Zaltrap drug candidate failed to meet targets in a late-stage study for the treatment of prostate cancer, though U.S. authorities were reviewing it for use in treating colon cancer.

Regeneron had said in December that Sanofi had withdrawn its application for marketing approval for Zaltrap and was planning to resubmit it early this year.

"The study did not meet the pre-specified criterion of improvement in overall survival," Sanofi said, referring to a Phase III study of Zaltrap, also known as aflibercept, in treating prostate cancer.

Sanofi added in a statement on Thursday that the U.S. Food and Drug Administration had granted a priority review to the companies to examine Zaltrap in the treatment of colon cancer. The FDA is due to give a decision by August 4.

Priority review is granted to a drug if preliminary estimates show it has the potential to provide a treatment where no adequate therapy exists or a significant improvement compared with marketed products, Sanofi said.

"Sanofi and Regeneron are committed to the continued development of Zaltrap," Sanofi oncology head Debasish Roychowdhury said in the statement.

(Reporting by Nina Sovich; Editing by James Regan)

FILED UNDER:

Ebola Watch

Feature: Africa's medicine men key to halting Ebola spread in Guinea

Feature: Africa's medicine men key to halting Ebola spread in Guinea

In a land where witchcraft is sought after more than science for curing illness, medicine men in Guinea say the Ebola epidemic would be over by now if they had been properly included in the outbreak response.  Full Article 

Reuters Showcase

India Cricket Chief

India Cricket Chief

Former ICC boss Dalmiya returns as BCCI chief.  Full Article 

S&P on Budget

S&P on Budget

Budget shows commitment to keep fiscal deficit low - S&P.  Full Article 

Richie Rich

Richie Rich

Bill Gates tops Forbes rich list, Michael Jordan joins.  Full Article 

Mega Buy

Mega Buy

HP to buy Wi-Fi gear maker Aruba Networks for $2.7 bln.  Full Article 

Blogger's Murder

Blogger's Murder

Bangladesh says arrests main suspect in U.S. blogger Avijit Roy's killing.  Full Article 

Alleged Threats

Alleged Threats

Twitter, law enforcement investigate alleged Islamic State threats.  Full Article 

New Tour

New Tour

Pop icon Madonna announces dates for 'Rebel Heart' tour.  Full Article 

Lathmar Holi

In Pics: Lathmar Holi

Images of "Lathmar Holi" at Nandgaon in Uttar Pradesh.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage